联合化疗治疗原发灶不明的腺癌
Combination chemotherapy in the treatment of adenocarcinoma of unknown primary origin.
作者信息
Walach N, Horn Y
出版信息
Cancer Treat Rep. 1987 Jun;71(6):605-7.
A total of 21 patients with histologic diagnosis of metastatic adenocarcinoma and an occult primary tumor were treated with combination chemotherapy. The regimen consisted of cyclophosphamide, vincristine, methotrexate, and 5-fluorouracil (COMF). The overall response rate was 47.6%. Six patients (28.6%) achieved complete response (mean duration, 36.5 months) and four patients (19%) achieved partial response (mean duration, 7.7 months). Toxicity was manageable and occurred in 14 patients (67%). The COMF combination serves as a broad-spectrum chemotherapy regimen in adenocarcinoma of unknown primary origin.
共有21例经组织学诊断为转移性腺癌且原发肿瘤隐匿的患者接受了联合化疗。化疗方案包括环磷酰胺、长春新碱、甲氨蝶呤和5-氟尿嘧啶（COMF）。总缓解率为47.6%。6例患者（28.6%）达到完全缓解（平均持续时间36.5个月），4例患者（19%）达到部分缓解（平均持续时间7.7个月）。毒性反应可控，14例患者（67%）出现毒性反应。COMF联合方案是一种用于原发灶不明腺癌的广谱化疗方案。
Zotero 插件